Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [14C]-Fosgonimeton
Fosgonimeton · 1 trial · 1 indication
Total radioactivity recovery (fet1-t2)
Total radioactivity recovery (fet1-t2) through routes of elimination (urine and feces).
Cmax will be determined from plasma samples.
Tmax will be determined from plasma samples
AUC will be determined from plasma samples.
t1/2 will be determined from plasma samples.
| Arm | Type | Description |
|---|---|---|
| Dosing Group | EXPERIMENTAL | All 8 subjects will receive a single dose of study drug |
| Name | Type | Description |
|---|---|---|
| [14C]-Fosgonimeton | DRUG | Carbon-14 Radiolabeled Fosgonimeton |
Inclusion Criteria: 1. Males, of any race, between 18 and 60 years of age, inclusive. 2. Body mass index between 18.0 and 32.0 kg/m2, inclusive. 3. In good health, determined by the investigator's discretion 4. Subjects and their partners will agree to use contraception during their participation 5...
Fosgonimeton is a small molecule drug candidate developed by LeonaBio, Inc. (ticker LONA). It is in Phase 1 clinical development, and its specific therapeutic indications have not been disclosed. The compound has been studied in a single completed Phase 1 trial involving healthy male volunteers.
Fosgonimeton is being developed by LeonaBio, Inc., which trades under the ticker symbol LONA. LeonaBio is the sponsor of the clinical program for Fosgonimeton.
Fosgonimeton is in Phase 1 clinical development. It has completed one Phase 1 trial and has no active trials at this time. The drug is investigational and has not been approved by the FDA.
Fosgonimeton has been evaluated in one completed Phase 1 trial, NCT05511558, titled "A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017)." The trial enrolled 8 healthy male volunteers in the United States and was completed.
Yes, [14C]-Fosgonimeton is an alternative name for Fosgonimeton. The carbon-14 labeled version, [14C]-Fosgonimeton, was used in the Phase 1 trial NCT05511558 to study the absorption, metabolism, and excretion of the drug.